Comparative Pharmacology
Head-to-head clinical analysis: HYDRO D versus SALURON.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HYDRO D versus SALURON.
HYDRO-D vs SALURON
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Thiazide diuretic that inhibits the sodium-chloride symporter (NCC) in the distal convoluted tubule, reducing sodium and water reabsorption and increasing potassium excretion.
Saluron (hydroflumethiazide) is a thiazide diuretic that inhibits the sodium-chloride symporter (NCC) in the distal convoluted tubule of the nephron, increasing excretion of sodium, chloride, and water. It also reduces peripheral vascular resistance through direct vasodilatory effects.
25-100 mg orally once daily in the morning.
Initial: 50-100 mg orally once daily; maintenance: 50-200 mg orally once daily or in divided doses.
None Documented
None Documented
Terminal elimination half-life: 5.6 to 15 hours; prolonged in renal impairment and in patients with heart failure.
Terminal elimination half-life is 8-12 hours in adults with normal renal function; prolonged in renal impairment (up to 24-36 hours with creatinine clearance <30 mL/min).
Renal: approximately 50% as unchanged drug; biliary/fecal: approximately 50% as metabolites and minor unchanged drug.
Primarily renal (≥95%) via glomerular filtration and tubular secretion; approximately 70% as unchanged drug, 25% as metabolites. Biliary/fecal excretion accounts for <5%.
Category C
Category C
Thiazide Diuretic
Thiazide Diuretic